Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Supernus Pharmaceuticals Inc. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 actions are being reviewed by 3 distinct examiners, ensuring that each application receives an independent evaluation from a different individual at the USPTO. This diversity of examiners can provide a range of feedback on the company's pharmaceutical claims. The count of 3 examiners matches the 3 pending office actions.
While there are 3 examiners, the 3 pending office actions are concentrated within only 2 distinct art units. This suggests that the company's current filings are focused on specific technical areas within biotechnology. YOO, SUN JAE is the busiest examiner, holding 1 pending office action. Since this 1 action is only one of the 3 total pending office actions, the company's prosecution is not dependent on any single examiner.
The concentration in 2 art units indicates a focused departmental interaction. With 3 distinct examiners working within only 2 distinct art units, the company may encounter different individual styles but will likely face consistent departmental policies. This balance between 3 examiners and 2 art units requires a prosecution strategy that is both individually tailored and departmentally aware. YOO, SUN JAE handles the busiest_examiner_pending count of 1.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.6% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18899299 | SUBSTITUTED DERIVATIVES OF ISOINDOLES AND USES THEREOF | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18784106 | SUBSTITUTED DERIVATIVES OF ISOINDOLES | TOWNSLEY, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18899299 | SUBSTITUTED DERIVATIVES OF ISOINDOLES AND USES THEREOF | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18784106 | SUBSTITUTED DERIVATIVES OF ISOINDOLES | TOWNSLEY, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18999866 | DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF | YOO, SUN JAE | 1621 | §112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18899299 | SUBSTITUTED DERIVATIVES OF ISOINDOLES AND USES THEREOF | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §101§102§112DP | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18784106 | SUBSTITUTED DERIVATIVES OF ISOINDOLES | TOWNSLEY, SARA ELIZABETH | 1629 | §102§103§112DP | Non-Final OA | — | Pending | Jul 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSupernus Pharmaceuticals Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Sun Jae Yoo has the most, with 1 of Supernus Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
